Functional imaging of the salivary glands for evaluation of radiation-induced sialadenitis before and after Lu-177 PSMA radioligand therapy

被引：0
|
作者：
Langbein, T. [1 ]
Kulkarni, H. R. [1 ]
Singh, A. [1 ]
Baum, R. P. [1 ]
机构：
[1] Zent Klin Bad Berka, Bad Berka, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-587
引用
收藏
页码：S328 / S328
页数：1
相关论文
共 50 条
  • [1] Variation in the absorbed radiation dose and PSA response after serial Lu-177 PSMA radioligand therapy
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Singh, A.
    Shahinfar, M.
    Muller, D.
    Lehmann, C.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S202 - S202
  • [2] Serial dosimetry during Lu-177 PSMA radioligand therapy in the same patient
    Kulkarni, Harshad
    Schuchardt, Christiane
    Singh, Aviral
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [3] PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.
    Hotta, Masatoshi
    Gafita, Andrei
    Murthy, Vishnu
    Benz, Matthias R.
    Sonni, Ida
    Burger, Irene
    Eiber, Matthias
    Emmett, Louise
    Farolfi, Andrea
    Fendler, Wolfgang Peter
    Hofman, Michael S.
    Hope, Thomas A.
    Kratochwil, Clemens
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] PSMA Radioligand Therapy of Metastasized Prostate Cancer Using Lu-177 PSMA I&T and Lu-177 PSMA-617: First comparative Dosimetric Results
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S36 - S37
  • [5] PSMA Radioligand Therapy (PRLT) using Lu-177 PSMA I&T and Lu-177 PSMA-617: Intra-individual comparison of kinetics and dosimetry
    Schuchardt, C.
    Kulkarni, H. R.
    Wiessalla, S.
    Shahinfar, M.
    Singh, A.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S214 - S214
  • [6] Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management
    Mahajan, Sonia
    Grewal, Ravinder K.
    Friedman, Kent P.
    Schoder, Heiko
    Pandit-Taskar, Neeta
    TRANSLATIONAL ONCOLOGY, 2022, 21
  • [7] Is Lu-177 PSMA radioligand therapy of prostate cancer safe for patients with single functioning kidney?
    Singh, A.
    Schuchardt, C.
    Kulkarni, H.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S413 - S414
  • [8] Lu-177 PSMA Radioligand Therapy as Salvage Treatment in Metastatic Castration-Resistant Prostate Cancer
    Kulkarni, H. R.
    Singh, A.
    Schuchardt, C.
    Langbein, T.
    Zhang, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S287 - S288
  • [9] Radiation Toxicity Concerning Salivary and Lachrymal Glands Caused by Peptide Radioligand Therapy Using a Lu-177 PSMA Inhibitor (I&T) in Patients with Metastasized Prostate Cancer: First in Human Studies
    Ozkan, A.
    Schuchardt, C.
    Kulkarni, H.
    Shahinfar, M.
    Sayeg, M.
    Baum, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S337 - S338
  • [10] Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer
    Kulkarni, Harshad
    Schuchardt, Christiane
    Singh, Aviral
    Langbein, Thomas
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
12345